Clinical Trials Logo

Pancreatic Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Ductal Adenocarcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04779151 Suspended - Clinical trials for Head and Neck Cancer

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

NIRADO
Start date: April 7, 2021
Phase: Phase 2
Study type: Interventional

Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles, and then every 42 days. Disease will be assessed every 2 cycles (6 weeks) from C3D1 by CT-scan (or MRI or bone scan, if relevant). Patients still under treatment after 1 year may have tumor evaluation spaced out every 3 cycles

NCT ID: NCT04111172 Suspended - Clinical trials for Malignant Solid Neoplasm

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Start date: November 10, 2020
Phase: Phase 2
Study type: Interventional

This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.

NCT ID: NCT03444948 Suspended - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

EUS-RFA
Start date: February 14, 2019
Phase: N/A
Study type: Interventional

To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients with inoperable pancreatic cancer confers survival benefit when compared to patients receiving standard medical care.